| Bioactivity | LSD1-IN-25 (Compound 9j) is a potent, selective and orally active LSD1 inhibitor with an IC50 of 46 nM (Ki = 30.3 nM). LSD1-IN-25 induces cancer cell apoptosis[1]. |
| Invitro | LSD1-IN-25 (Compound 9j; 0-20 μM; 72 h) 抑制实体瘤细胞增殖[1]。LSD1-IN-25 (1-4 μM; 24 h) 诱导细胞 H3K4me2 升高，抑制 H1650 细胞的 EMT 过程[1]。LSD1-IN-25 (1-4 μM; 24 h) 诱导 H1650 细胞凋亡和 S 阻滞[1]。 Cell Proliferation Assay[1] Cell Line: |
| In Vivo | LSD1-IN-25 (Compound 9j; 10 and 20 mg/kg; oral; once daily for 21 days) 在 H1650 细胞的小鼠异种移植模型中显示出抗肿瘤活性[1]。 Animal Model: |
| Name | LSD1-IN-25 |
| Formula | C32H33ClN6O3S |
| Molar Mass | 617.16 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Li Z, et al. Design, synthesis and in vitro/in vivo anticancer activity of tranylcypromine-based triazolopyrimidine analogs as novel LSD1 inhibitors. Eur J Med Chem. 2023 May 5;253:115321. |